Cancer Letters
Volume 206, Issue 2 , Pages 181-191 , 8 April 2004

Rho GTPases: potential candidates for anticancer therapy

Received 29 July 2003 ,Accepted 4 August 2003.

References 

  1. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling network. Genes Dev. 1997;11:2295–2322
  2. Aznar S, Lacal JC. Searching new targets for anticancer drug design: the families of Ras and Rho GTPases and their effectors. Prog. Nucleic Acid. Res. Mol. Biol. 2001;67:193–234
  3. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett. 2001;165:1–10
  4. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227–238
  5. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol. 2000;11:471–477
  6. Schmit AAP, Govek E-E, Bottner B, Van Aelst L. Rho GTPases: signaling, migration and invasion. Exp. Cell Res. 2002;261:1–12
  7. Settleman J. Rac'n Rho: the music that shapes a developing embryo. Dev. Cell. 2001;1:321–331
  8. Settleman J. Getting in shape with Rho. Nat. Cell Biol. 2000;2:E7–E9
  9. Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene. 2002;286:155–174
  10. Ballestero RP, Esteve P, Perona P, Jiménez B, Lacal JC. Biological function of Aplysia californica rho gene. The superfamily of Ras related genes. NATO Advanced Science Institute Series. vol. A220. 2000; pp. 237–242
  11. Perona R, Esteve P, Jimenez P, Ballestero RP, Ramon y Cajal R, Lacal JC. Tumorigenic activity of rho genes from Aplysia californica. Oncogene. 1993;8:1285–1292
  12. van Leeuwen FN, van der Kammen RA, Habets GG, Collard J. Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. Oncogene. 1995;11:2215–2221
  13. Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG. A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature. 1995;375:338–340
  14. del Peso L, Hernandez-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C, et al. Rho proteins induce metastatic properties in vivo. Oncogene. 1997;15:3047–3057
  15. Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001;171:1–10
  16. McCormick F. Signal transduction. Why Ras needs Rho. Nature. 1998;394:220–221
  17. Khosravi-Far R, Campbell S, Rossman K, Der CJ. Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv. Cancer Res. 1998;72:57–107
  18. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc. Natl Acad. Sci. USA. 1995;92:11781–11785
  19. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature. 1995;37:457–459
  20. Qiu RG, Abo A, McCormick F, Symons M. Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol. Cell Biol. 1997;17:3449–3458
  21. Nur-E-Kamal MS, Kamal JM, Qureshi MM, Maruta H. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation. Oncogene. 1999;18:7787–7793
  22. Boerner JL, Danielsen AJ, McManus MJ, Maihle NJ. Activation of Rho is required for ligand-independent oncogenic signaling by a mutant EGF receptor. J. Biol. Chem. 2000;10:3691–3695
  23. Kim BC, Yi JY, Yi SJ, Shin IC, Ha KS, Jhun BH, et al.  Rac GTPase activity is essential for EGF-induced mitogenesis. Mol. Cells. 1998;8:90–95
  24. Sachdev P, Jiang XY, Li W, Miki T, Nur-E-Kamal MS, Wang LH. Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J. Biol. Chem. 2001;276:26461–26471
  25. Barone MW, Sepe L, Melillo RM, Mineo A, Santelli G, Monaco C, et al.  RET/PTC1 oncogene signaling in PC C134 thyroid cells requires the small GTP-binding protein Rho. Oncogene. 2001;20:6973–6982
  26. Royal I, Lamarche-Vane N, Lamorte L, Kaibuchi K, Park M. Activation of Cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulate epithelial cell colony spreading and dissociation. Mol. Biol. Cell. 2000;11:1709–1725
  27. Kamei T, Matozaki T, Sakisaka T, Kodama A, Oyama S, Peng YF, et al.  Coendocytosis of cadherin and c-Met to disruption of cell–cell adhesion in MDCK cells: regulation by Rho, Rac and Rab small G proteins. Oncogene. 1999;18:6776–6784
  28. Whitehead IP, Zohn IE, Der CJ. Rho GTPase-dependent transformation by G protein-coupled receptors. Oncogene. 2001;20:1547–1555
  29. Vidal A, Millard SS, Miller JP, Koff A. Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status. J. Biol. Chem. 2002;277:16433–16440
  30. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27 (Kip1) expression in the vasculature of hypertensive rats. Circ. Res. 2000;89:488–495
  31. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1). J. Biol. Chem. 1999;274:21926–21931
  32. Liberto M, Cobrinik D, Minden A. Rho regulates p21 (CIP1), cyclin D1, and checkpoint control in mammary epithelial cells. Oncogene. 2002;21:1590–1599
  33. Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21 (WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol. Cell Biol. 1998;18:6962–6970
  34. Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature. 1998;394:295–299
  35. Gjoerup O, Lukas J, Bartek J, Willumsen BM. Rac and Cdc42 are potent stimulators of E2F-dependent transcription capable of promoting retinoblastoma susceptibility gene product hyperphosphorylation. J. Biol. Chem. 1998;273:18812–18818
  36. Bourdoulous S, Orend G, MacKenna DA, Pasqualini R, Ruoslahti E. Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. J. Cell Biol. 1998;143:267–276
  37. Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21 (WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol. Cell Biol. 1998;18:6962–6970
  38. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscleproliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1). J. Biol. Chem. 1999;274:21926–21931
  39. Danen EH, Sonneveld P, Sonnenberg A, Yamada KM. Dual stimulation of Ras/mitogen-activated protein kinase and RhoA by cell adhesion to fibronectin supports growth factor-stimulated cell cycle progression. J. Cell Biol. 2000;151:1413–1422
  40. Hansen LK, Albrecht JH. Regulation of the hepatocyte cell cycle by type I collagen matrix: role of cyclin D1. J. Cell Sci. 1999;112:2971–2981
  41. Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H. A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J. Hepatol. 2000;32:762–770
  42. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27 (Kip1) expression in the vasculature of hypertensive rats. Circ. Res. 2001;89:488–495
  43. Hu W, Bellone CJ, Baldassare JJ. RhoA stimulates p27 (Kip) degradation through its regulation of cyclin E/CDK2 activity. J. Biol. Chem. 1999;274:3396–3401
  44. Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat. Cell Biol. 2001;3:950–957
  45. Coniglio SJ, Jou TS, Symons M. Rac1 protects epithelial cells against anoikis. J. Biol. Chem. 2001;276:28113–28120
  46. Zugasti O, Rul W, Roux P, Peyssonnaux C, Eychene A, Franke TF, et al.  Raf–MEK–Erk cascade in anoikis is controlled by Rac1 and Cdc42 via Akt. Mol. Cell Biol. 2001;21:6706–6717
  47. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett. 2001;165:1–10
  48. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS. Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J. Biol. Chem. 2000;275:423–428
  49. Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell Biol. 1999;144:1235–1244
  50. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol. 2001;11:471–477
  51. Ridley AJ. Rho GTPases and cell migration. J. Cell Sci. 2001;114:2713–2722
  52. Price LS, Collard JG. Regulation of the cytoskeleton by Rho-family GTPases: implications for tumour cell invasion. Semin. Cancer Biol. 2001;11:167–173
  53. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227–238
  54. Sander EE, Collard JG. Rho-like GTPases: their role in epithelial cell–cell adhesion and invasion. Eur. J. Cancer. 1999;35:1905–1911
  55. Gopalakrishnan S, Dunn KW, Marrs JA. Rac1, but not RhoA, signaling protects epithelial adherens junction assembly during ATP depletion. Am. J. Physiol. Cell Physiol. 2002;283:C261–C272
  56. Kaartinen V, Haataja L, Nagy A, Heisterkamp N, Groffen J. TGFbeta3-induced activation of RhoA/Rho-kinase pathway is necessary but not sufficient for epithelio-mesenchymal transdifferentiation: implications for palatogenesis. Int. J. Mol. Med. 2002;9:563–570
  57. Hirase T, Kawashima S, Wong EY, Ueyama T, Rikitake Y, Tsukita S, et al.  Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms. J. Biol. Chem. 2001;276:10423–10431
  58. Hopkins AM, Walsh SV, Verkade P, Boquet P, Nusrat A. Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function. J. Cell Sci. 2003;116:725–742
  59. Sahai E, Marshall CJ. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat. Cell Biol. 2002;4:408–415
  60. Zhong C, Kinch MS, Burridge K. Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells. Mol. Biol. Cell. 1997;8:2329–2344
  61. Nakamoto M, Teramoto H, Matsumoto S, Igishi T, Shimizu E. K-ras and rhoA mutations in malignant pleural effusion. Int. J. Oncol. 2001;19:971–976
  62. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, et al.  Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br. J. Cancer. 1998;177:147–152
  63. Benitah SA, Espina C, Valerón PF, Lacal JC. Rho GTPases in human carcinogenesis: a tale of excess. Rev. Oncol. 2003;5:70–78
  64. Symons M, Derry J, Karlak B, Jiang S, Lemahieu L, McCormick F, et al.  Wiskott–Aldrich protein, a novel effector for the GTPases CDC42Hs is implicated in actin polymerization. Cell. 1996;84:723–734
  65. Derry J, Ochs J, Francke U. Isolation of a novel gene mutated in Wiskott–Aldrich syndrome. Cell. 1996;78:635–644
  66. Aspenstrom P, Lindberg L, Hall A. Two GTPases Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott–Aldrich syndrome. Curr. Biol. 1996;6:70–75
  67. Linder S, Nelson D, Weiss M, Aepfelbacher M. Wiskott–Aldrich syndrome protein regulates podosomes in primary human macrophages. Proc. Natl Acad. Sci. USA. 1999;96:9648–9653
  68. Yarar D, To W, Abo A, Welch MD. The Wiskott–Aldrich syndrome protein directs actin-based motility by stimulating actin nucleation with the Arp2/3 complex. Curr. Biol. 1999;9:555–558
  69. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. Eur. Mol. Biol. Org. J. 1998;17:6932–6941
  70. Van Aelst L, Joneson T, Bar-Sagi D. Indentification of a novel Rac1-interacting protein involved in membrane ruffling. Eur. Mol. Biol. Org. J. 1996;15:3778–3786
  71. Miki H, Fukuda M, Nishida E, Takenawa T. Phosphorylation of WAVE downstream of mitogen-activated protein kinase signaling. J. Biol. Chem. 1999;274:27605–27609
  72. Sossey-Alaoui K, Su G, Malaj E, Roe B, Cowell JK. WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t (1;13)(q21;q12) chromosome translocation in a patient with ganglioneuroblastoma. Oncogene. 2002;21:5967–5974
  73. Sturge J, Hamelin J, Jones GE. N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator. J. Cell Sci. 2001;115:699–711
  74. Mizutani K, Miki H, He H, Maruta H, Takenawa T. Essential role of neural Wiskott–Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts. Cancer Res. 2002;62:669–674
  75. Kim A, Kakalis L, Abdul-Manan N, Liu G, Rosen M. Autoinhibition and activation mechanisms of the Wiskott–Aldrich syndrome protein. Nature. 2000;404:151–158
  76. Kuroda S, Fukata M, Nakagawa M, Kaibuchi K. Cdc42, Rac1 and their effector IQGAP1 as molecular switches for cadherin-mediated cell–cell adhesion. Biochem. Biophys. Res. Commun. 1999;262:1–6
  77. Kuroda S, Fukata M, Nakagawa M, Fujii K, Nakamura T, Ookubo T, et al.  Role of IQGAP1, a target of the small GTPase Cdc42 and Rac1, in regulation of E-cadherin-mediated cell–cell adhesion. Science. 1998;281:832–835
  78. Fukata M, Kuroda S, Nakagawa M, Kawajiri A, Itoh N, Shoji I, et al.  Cdc42 and rac1 regulate the interaction of IQGAP1 with b-catenin. J. Biol. Chem. 1999;274:26044–26050
  79. Takemoto H, Doki Y, Shiozaki H, Imamura H, Utsunomiya T, Miyata H, et al.  Localization of IQGAP1 is inversely correlated with intercellular adhesion mediated by e-cadherin in gastric cancers. Int. J. Cancer. 2001;91:783–788
  80. Li S, Wang Q, Chakladar A, Bronson RT, Bernards A. Gastric hyperplasia in mice lacking the putative Cdc42 effector IQGAP1. Mol. Cell Biol. 2000;20:697–701
  81. Shimao Y, Nabeshima K, Inoue T, Koono M. Complex formation of IQGAP1 with E-cadherin/catenin during cohort migration of carcinoma cells. Its possible association with localized release from cell–cell adhesion. Virchows Arch. 2002;441:124–132
  82. Briggs MW, Li Z, Sacks DB. IQGAP1-mediated stimulation of transcriptional co-activation by beta-catenin is modulated by calmodulin. J. Biol. Chem. 2002;277:7453–7465
  83. Swart-Mataraza JM, Li Z, Sacks DB. IQGAP1 is a component of Cdc42 signaling to the cytoskeleton. J. Biol. Chem. 2002;277:24753–24763
  84. Teo M, Manser E, Lim L. Identification and molecular cloning of a p21Cdc42/Rac1-activated serine/threonine kinase that is rapidly activated by thrombin in platelets. J. Biol. Chem. 1995;270:26690–26697
  85. Bagrodia S, Taylor SJ, Jordon KA, Van Aelst L, Cerione R. A novel regulator of p21-activated kinases. J. Biol. Chem. 1998;273:23633–23636
  86. Kumar R, Vadlamudi RK. Emerging functions of p21-activated kinases in human cancer cells. J. Cell Physiol. 2002;193:133–144
  87. Sachdev PR, Zeng L, Wang LH. Distinct role of phosphatidylinositol-3-kinase and Rho family GTPases in Vav3-induced cell transformation, cell motility and morphological changes. J. Biol. Chem. 2002;277:17638–17648
  88. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J, et al. Kinase-defective Pak1 mutants inhibit ras transformation of Rat-1 fibroblasts. Mol. Cell Biol. 1998;17:4454–4464
  89. Tang Y, Yu J, Field J. Signals from the Ras, Rac, and Rho GTPases converge on the Pak protein kinase in Rat-1 fibroblasts. Mol. Cell Biol. 1999;19:1881–1891
  90. He H, Hirokawa Y, Manser E, Lim L, Levitzki A, Maruta H. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J. 2001;7:191–202
  91. Gnesutta N, Qu J, Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J. Biol. Chem. 2001;276:14414–14419
  92. Tang Y, Zhou H, Chen A, Pittman RN, Field J. The Akt proto-oncogene links Ras to Pak and cell survival. J. Biol. Chem. 2000;275:9106–9109
  93. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, et al.  Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J. Biol. Chem. 2002;277:550–558
  94. Adam D, Vadlamudi R, Mandal M, Chernoff J, Kumar R. Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase Dead p21-activated kinase-1. J. Biol. Chem. 2000;275:12041–12050
  95. Vadlamudi R, Adam L, Wang R-A, Mandal M, Nguyen D, Sahin A, et al.  Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J. Biol. Chem. 2000;275:36238–36244
  96. Salh B, Marotta A, Wagey R, Sayed M, Pelech S. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int. J. Cancer. 2002;98:148–154
  97. Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, et al.  The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J. 2002;8:328–336
  98. Nakagawa N, Fujisawa K, Ishizaki T, Saito Y, Nakao Y, Narumiya S. ROCKI and ROCKII, two isoforms of Rho-associated coiled-coil forming proteins kinase in mice. Fed. Eur. Biochem. Soc. Lett. 1996;392:189–193
  99. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, et al.  Rho-associated kinase, a novel serine/threonine kinase as a putative target for small GTP binding protein Rho. Eur. Mol. Biol. Org. J. 1996;15:2208–2216
  100. Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y, et al. P160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesion. Fed. Eur. Biochem. Soc. Lett. 1997;404:118–124
  101. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROKa is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell Biol. 1996;16:5313–5327
  102. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Mastuura Y, et al. Formation of actin stress fibers and focal adhesion enhanced by Rho-kinase. Science. 1997;275:1308–1311
  103. Hirose H, Ishizaki T, Watanabe N, Uehata M, Kranenburg O, Moolenaar W, et al.  Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115. J. Cell Biol. 1998;141:1625–1636
  104. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinase. Mol. Pharmacol. 2000;57:976–983
  105. Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by Rho requires activity of ROCK kinases. Curr. Biol. 1999;9:136–145
  106. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999;5:221–225
  107. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H, Hirohashi S. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology. 2001;33:577–581
  108. Genda T, Sakamoto M, Ichida T, Asakura H, Kojiro M, Narumiya S, et al. Cell motility mediated by Rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology. 1999;30:1027–1036
  109. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun. 2000;269:652–659
  110. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW. Rho-kinase (ROK) promotes CD44v (3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil. Cytoskeleton. 1999;43:269–287
  111. Jo M, Thomas KS, Somlyo AV, Somlyo AP, Gonias SL. Cooperativity between the Ras–ERK and Rho–Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J. Biol. Chem. 2002;277:12479–12485
  112. Wicki A, Niggli V. The Rho/Rho-kinase and phosphatidylinositol 3-kinase pathways are essential for the spontaneous locomotion of Walker 256 carcinosarcoma cells. Int. J. Cancer. 2001;91:763–771
  113. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, et al.  Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer celllines: an in vitro study. Carcinogenesis. 2001;22:1139–1148
  114. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al.  3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology. 2002;122:308–317
  115. Aznar Benitah S, Valeron PF, del Rincon SV, Perez LF, Perona R, Lacal JC. Simultaneous tyrosine and serine phosphorylation of Stat3 transcription factor is involved in RhoA gtpase oncogenic transformation. Mol. Biol. Cell. 2001;12:3282–3294
  116. Benitah SA, Valerón PF, Rui H, Lacal JC. Stat5a mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. Mol. Biol. Cell. 2003;14:40–53
  117. Benitah SA, Valerón PF, Lacal JC. ROCK and NFκB-dependent activation of COX-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol. Biol. Cell. 2003;14:3041–3054
  118. Sotiropoulos A, Gineitis D, Copeland J, Treisman R. Signal-regulated activation of serum response factor is mediated by changes in actin dynamic. Cell. 1999;98:159–169
  119. Psichari E, Balmain A, Plows D, Zoumpourlis V, Pintzas A. High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. J. Biol. Chem. 2003;277:29490–29495
  120. Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, et al.  Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J. Biol. Chem. 1999;274:25245–25249
  121. Whitehead IP, Lambert QT, Glaven JA, Abe K, Rossman KL, Mahon GM, et al.  Dependence of Dbl and Dbs transformation on MEK and NF-kB activation. Mol. Cell Biol. 1999;19:7759–7770
  122. Muller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep L, Buettner R, et al. The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. Eur. Mol. Biol. Org. J. 2002;21:736–748

PII: S0304-3835(03)00637-2

doi: 10.1016/j.canlet.2003.08.035

Cancer Letters
Volume 206, Issue 2 , Pages 181-191 , 8 April 2004

Article Tools

* Image Usage & Resolution